The combination of PMIBcr/Abl‐R6 efficiently kills imatinib‐resistant both CML and ALL cell lines, and we proved that PMIBcr/Abl‐R6 could induce different Bcr/Abl isoforms regarding the Abl kinase domain structure. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.